{"id":3659,"company":{"country":"CH","currency":"CHF","exchange":"NASDAQ NMS - GLOBAL MARKET","ipo":"2016-09-23","marketCap":326.119,"name":"AC Immune SA","phone":"41213459121","outstanding":83.62,"symbol":"ACIU","website":"https://www.acimmune.com/","industry":"Biotechnology"},"price":3.5975,"year":2024,"month":5,"day":25,"weekday":"Saturday","title":"Financial Performance Analysis of AC Immune SA","date":"2024-05-25","url":"/posts/2024/05/25/ACIU","content":[{"section":"Revenue","text":"AC Immune SA has experienced consistent revenue growth over the past few years. In 2020, the company reported revenue of $27.8 million, which increased by 14.8% compared to the previous year. This growth can be attributed to successful partnerships and collaborations, as well as the progress in the development of their pipeline products."},{"section":"Earnings","text":"While AC Immune SA has not yet achieved profitability, their earnings performance has been improving. The company reported a net loss of $42.6 million in 2020, which decreased by 11.1% compared to the previous year. AC Immune's efforts to control expenses and increase their product portfolio have contributed to this positive trend."},{"section":"Cash Flow","text":"AC Immune SA has maintained a positive cash flow in recent years. In 2020, the company generated $27.4 million in operating cash flow, indicating their ability to generate cash from their core operations. This positive cash flow provides AC Immune with the necessary resources for research and development, as well as other business activities."},{"section":"Investment Outlook","text":"AC Immune SA's financial performance suggests a promising investment outlook. The company's consistent revenue growth, improving earnings, and positive cash flow indicate their ability to generate value for shareholders. Additionally, AC Immune's focus on developing innovative therapies targeting neurodegenerative diseases positions them well in a growing market. However, investors should consider the risks associated with the biopharmaceutical industry, including clinical trial outcomes and regulatory approvals."},{"section":"Conclusion","text":"In conclusion, AC Immune SA has demonstrated a positive financial performance in recent years. Their revenue growth, improving earnings, and positive cash flow reflect the company's progress in advancing their pipeline products. With their focus on neurodegenerative diseases and successful partnerships, AC Immune has promising prospects in the biopharmaceutical industry."}],"tags":["CrossOver21","Long","Biotechnology"],"news":[{"category":"company","date":1716456480,"headline":"e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday","id":127865087,"image":"","symbol":"ACIU","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3509129657"},{"category":"company","date":1716294801,"headline":"Individual investors own 24% of AC Immune SA (NASDAQ:ACIU) shares but private equity firms control 30% of the company","id":127819891,"image":"https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","symbol":"ACIU","publisher":"Yahoo","summary":"Key Insights The considerable ownership by private equity firms in AC Immune indicates that they collectively have a...","url":"https://finance.yahoo.com/news/individual-investors-own-24-ac-123321438.html"},{"category":"company","date":1716278340,"headline":"AC Immune SA: Progress and Promise in Neurodegenerative Disease","id":127819513,"image":"","symbol":"ACIU","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3505536997"},{"category":"company","date":1716208500,"headline":"Week In Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal","id":127797369,"image":"","symbol":"ACIU","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3503613066"},{"category":"company","date":1715852760,"headline":"Biotech Alert: Searches spiking for these stocks today","id":127737645,"image":"","symbol":"ACIU","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3498768371"},{"category":"company","date":1715829000,"headline":"Buy Rating Justified by Strategic Partnerships and Promising Pipeline in AC Immune SA","id":127737646,"image":"","symbol":"ACIU","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3498352622"},{"category":"company","date":1715758380,"headline":"SPWR, BIG and BOLT among pre-market losers","id":127709029,"image":"","symbol":"ACIU","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3496682786"},{"category":"company","date":1715750100,"headline":"DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session","id":127709030,"image":"","symbol":"ACIU","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3496543860"},{"category":"company","date":1715688077,"headline":"Takeda agrees to develop active immunotherapy for Alzheimer's","id":127682026,"image":"","symbol":"ACIU","publisher":"Finnhub","summary":"Takeda and AC Immune SA have agreed a global option and license agreement for a potential first-in-class Abeta-targeting active immunotherapy for Alzheimer's.AC Immune's related immunotherapies...","url":"https://finnhub.io/api/news?id=faa429f20b45ef14996d973741c7fea31aedfb875dc9d5c5c0b83bcc976b9747"},{"category":"company","date":1715671920,"headline":"APP, MGNX and CYCC among pre-market losers","id":127681765,"image":"","symbol":"ACIU","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3494827692"},{"category":"company","date":1715664420,"headline":"Buy Rating Affirmed: AC Immune’s Promising Alzheimer’s Vaccine and Strategic Takeda Partnership","id":127686604,"image":"","symbol":"ACIU","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3494700842"},{"category":"company","date":1715630323,"headline":"Sector Update: Health Care Stocks Mixed Late Afternoon","id":127666097,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"ACIU","publisher":"Yahoo","summary":"Sector Update: Health Care Stocks Mixed Late Afternoon","url":"https://finance.yahoo.com/news/sector-health-care-stocks-mixed-195843729.html"},{"category":"company","date":1715625712,"headline":"Top Midday Gainers","id":127662784,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"ACIU","publisher":"Yahoo","summary":"Top Midday Gainers","url":"https://finance.yahoo.com/news/top-midday-gainers-184152520.html"},{"category":"company","date":1715613731,"headline":"Takeda shells out $100m to license AC Immune’s Phase II Alzheimer’s therapy","id":127661950,"image":"https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/05/shutterstock_1436567156.jpg","symbol":"ACIU","publisher":"Yahoo","summary":"Takeda will pay $100m upfront and up to $2.1bn in milestone-based payments for licensing AC immune’s amyloid beta-targeting immunotherapy.","url":"https://www.pharmaceutical-technology.com/news/takeda-shells-out-100m-to-license-ac-immunes-phase-ii-alzheimers-therapy/"},{"category":"company","date":1715603760,"headline":"FFIE, OGEN and CCLD among mid-day movers","id":127661181,"image":"","symbol":"ACIU","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3493296729"},{"category":"company","date":1715601960,"headline":"Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session","id":127659657,"image":"","symbol":"ACIU","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3493251115"},{"category":"company","date":1715601720,"headline":"Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune","id":127665820,"image":"https://www.biopharmadive.com/imgproxy/XiSUxOMmoLLweuJ4zEOj4jBAy55PQt-KFVto6G2jKK0/g:ce/rs:fill:770:435:0/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTQ5MDg3OTQ5MC5qcGc.webp","symbol":"ACIU","publisher":"Yahoo","summary":"The deal — worth $100 million up front and potentially billions more later on — gives Takeda an exclusive option to license an Alzheimer’s vaccine and other “active immunotherapies.”","url":"https://www.biopharmadive.com/news/takeda-alzheimers-ac-immune-immunotherapies/715913/"},{"category":"company","date":1715599587,"headline":"Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate","id":127657088,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"ACIU","publisher":"Yahoo","summary":"Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate","url":"https://finance.yahoo.com/news/takeda-pharmaceutical-ac-immune-agree-112627540.html"},{"category":"company","date":1715598360,"headline":"Crude Oil Surges Over 1%; Amprius Technologies Shares Plunge","id":127659255,"image":"","symbol":"ACIU","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3493159116"},{"category":"company","date":1715594700,"headline":"AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update","id":127657089,"image":"https://media.zenfs.com/en/globenewswire.com/5f79828fb0868f2a0f4d803192fe2df5","symbol":"ACIU","publisher":"Yahoo","summary":"AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update Landmark deal announced with Takeda for ACI-24.060 with $100 million upfront and total potential payments for option exercise and milestones of up to approximately $2.1 billionACI-24.060 ABATE Phase 2 trial on track to report Abeta-PET imaging results in Q2 2024, evaluating amyloid plaque reduction after 6 months of anti-Abeta active immunotherapyACI-7104.056 VacSYn Phase 2 trial of anti-a-syn active immunothe","url":"https://finance.yahoo.com/news/ac-immune-reports-first-quarter-100500061.html"},{"category":"company","date":1715594400,"headline":"AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease","id":127657090,"image":"https://media.zenfs.com/en/globenewswire.com/5f79828fb0868f2a0f4d803192fe2df5","symbol":"ACIU","publisher":"Yahoo","summary":"AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progressionAC Immune to receive upfront payment of $100 million upon closing and be eligible for an option exercise fee and additional potential milestones of up to approximately $2.1 billionAC","url":"https://finance.yahoo.com/news/ac-immune-takeda-sign-exclusive-100000575.html"},{"category":"company","date":1715590620,"headline":"AC Immune rockets 47% on Alzheimer's therapy deal with Takeda","id":127659257,"image":"","symbol":"ACIU","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3492973112"},{"category":"company","date":1715590260,"headline":"Alzheimer’s vaccine licensing deal boosts AC Immune","id":127659258,"image":"","symbol":"ACIU","publisher":"MarketWatch","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3492965477"},{"category":"company","date":1715587200,"headline":"Fly Intel: Pre-market Movers","id":127658179,"image":"","symbol":"ACIU","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3492899388"},{"category":"company","date":1715586660,"headline":"Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today?","id":127659262,"image":"","symbol":"ACIU","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3492886339"},{"category":"company","date":1715585700,"headline":"Why Is Safe \u0026 Green Development (SGD) Stock Down 5% Today?","id":127659263,"image":"","symbol":"ACIU","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3492866419"},{"category":"company","date":1715585192,"headline":"AC Immunity Shares Soar on Exclusive License Deal with Takeda","id":127655618,"image":"","symbol":"ACIU","publisher":"Finnhub","summary":"By Dean Seal Shares of AC Immunity surged after the company signed announced an agreement with Takeda Pharmaceutical for an exclusive option to license its active immunotherapy for...","url":"https://finnhub.io/api/news?id=66270b473a485e36b47d22a45a0b9149918bb17ccf0dd3bc753ad5acd578c8ea"},{"category":"company","date":1715584440,"headline":"Why Is AC Immune (ACIU) Stock Up 45% Today?","id":127659265,"image":"","symbol":"ACIU","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3492839945"},{"category":"company","date":1715581680,"headline":"AC Immune Partners with Takeda on Alzheimer’s Therapy","id":127659268,"image":"","symbol":"ACIU","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3492789701"},{"category":"company","date":1715581680,"headline":"AC Immune Reports Q1 2024 Financials","id":127659267,"image":"","symbol":"ACIU","publisher":"TipRanks","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3492789694"},{"category":"company","date":1715581620,"headline":"Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday","id":127659269,"image":"","symbol":"ACIU","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3492788039"},{"category":"company","date":1715580790,"headline":"AC Immune: Q1 Earnings Snapshot","id":127655154,"image":"","symbol":"ACIU","publisher":"Finnhub","summary":"LAUSANNE, Switzerland — LAUSANNE, Switzerland — AC Immune SA on Monday reported a loss of $20.4 million in its first quarter. The Lausanne, Switzerland-based company said it had a loss of...","url":"https://finnhub.io/api/news?id=9e7b6c2ad4dee0a6f7cdebb46676cd012ad363cbc61f1d7b915be3093383831f"},{"category":"company","date":1715578020,"headline":"AC Immune GAAP EPS of -$0.18 misses by $0.03","id":127659274,"image":"","symbol":"ACIU","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3492732238"},{"category":"company","date":1715577060,"headline":"AC Immune reports Q1 EPS (18c), consensus (15c)","id":127659275,"image":"","symbol":"ACIU","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3492719100"},{"category":"company","date":1715576760,"headline":"AC Immune, Takeda sign worldwide option and license agreement","id":127659276,"image":"","symbol":"ACIU","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3492715426"},{"category":"company","date":1715565360,"headline":"ACIU Stock Earnings: AC Immune Misses EPS for Q1 2024","id":127686607,"image":"","symbol":"ACIU","publisher":"InvestorPlace","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3493421747"},{"category":"company","date":1715564160,"headline":"Gold Down Over 1%; AC Immune Shares Spike Higher","id":127663283,"image":"","symbol":"ACIU","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3493392119"}]}